Cited by 225Drug Solubulity and Delivery SystemsAdvanced Drug Delivery SystemsAdvancements in Transdermal Drug Delivery

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Review and analysis of FDA approved drugs using lipid-based formulations

Open access

Savla, Ronak, Browne, Jeff, Plassat, Vincent, Wasan, Kishor M., Wasan, Ellen K.·2017·Drug Development and Industrial Pharmacy

DOI 10.1080/03639045.2017.1342654

Open this paper in CoChat — free account

Abstract

Lipid-based drug delivery systems (LBDDS) are one of the most studied bioavailability enhancement technologies and are utilized in a number of U.S. Food and Drug Administration (FDA) approved drugs. While researchers have used several general rules of thumb to predict which compounds are likely to benefit from LBDDS, formulation of lipid systems is primarily an empiric endeavor. One of the challenges is that these rules of thumb focus in different areas and are used independently of each other. The Developability Classification System attempts to link physicochemical characteristics with possible formulation strategies. Although it provides a starting point, the formulator still has to empirically develop the formulation. This article provides a review and quantitative analysis of the molecular properties of these approved drugs formulated as lipid systems and starts to build an approach that provides more directed guidance on which type of lipid system is likely to be the best for a particular drug molecule.

Integrity signals

Registry

Crossref · 10.1080/03639045.2017.1342654

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
Solubilizing Excipients in Oral and Injectable Formulations
Strickley, R. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016235.32639.23 · Cited by 1,417
Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system
Pouton, C. W. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.04.016 · Cited by 1,306
Arzneimittelforschung
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies
Pouton, C. W., & Porter, C. J. H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.010 · Cited by 908
Oral lipid-based formulations
Hauss, D. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.006 · Cited by 597
Handbook of Aqueous Solubility Data
Yalkowsky, S. H. (2003) · CRC Press eBooks · doi:10.1201/9780203490396 · Cited by 586
Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration
Fleisher, D., Li, C., Zhou, Y., Pao, L., & Karim, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00004 · Cited by 512
ChemMine tools: an online service for analyzing and clustering small molecules
Backman, T. W. H., Cao, Y., & Girke, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr320 · Cited by 512
The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development
Butler, J., & Dressman, J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22217 · Cited by 452
Lipid-Based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.007 · Cited by 442
50 years of oral lipid-based formulations: provenance, progress and future perspectives
Feeney, O. M., Crum, M. F., McEvoy, C. L., Trevaskis, N. L., Williams, H. D., Pouton, C. W., Charman, W. N., Bergström, C. A. S., & Porter, C. J. H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.007 · Cited by 426
Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics†
Wacher, V. J., Silverman, J. A., Zhang, Y., & Benet, L. Z. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980082d · Cited by 423
Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.
Martins, S., Sarmento, B. F. C. C., Ferreira, D., & Souto, E. B. (2007) · PubMed Central · Cited by 399
Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs
Dahan, A., & Hoffman, A. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.021 · Cited by 349
Absorption Enhancement through Intracellular Regulation of Tight Junction Permeability by Medium Chain Fatty Acids in Caco-2 Cells
Lindmark, T., Kimura, Y., & Artursson, P. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37216-7 · Cited by 333
Absorption Enhancers: Applications and Advances
Aungst, B. J. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9307-4 · Cited by 309
Amphotericin B
Lemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 307
New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs
Müllertz, A., Ogbonna, A., Ren, S., & Rades, T. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01107.x · Cited by 301
Intestinal lymphatic transport for drug delivery
Yáñez, J. A., Wang, S. W. J., Knemeyer, I. W., Wirth, M., & Alton, K. B. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.019 · Cited by 288
The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats
Dahan, A., & Hoffman, A. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.01.017 · Cited by 234
Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs
Čerpnjak, K., Pobirk, A. Z., Gašperlin, M., & Vrečer, F. (2013) · Acta Pharmaceutica · doi:10.2478/acph-2013-0040 · Cited by 230
Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T. F., Gruner, S. M., Shyamsunder, E., & Täte, M. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6122 · Cited by 223
Influence of lipolysis on drug absorption from the gastro-intestinal tract
MacGregor, K. J., Embleton, J. K., Lacy, J. E., Perry, E., Solomon, L. J., Seager, H., & Pouton, C. W. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00489-9 · Cited by 220
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine
Porter, C. J. H., Kaukonen, A. M., Taillardat‐Bertschinger, A., Boyd, B. J., O'Connor, J. M., Edwards, G. A., & Charman, W. N. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20039 · Cited by 216
REDUCED INTER- AND INTRASUBJECT VARIABILITY IN CYCLOSPORINE PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH A MICROEMULSION FORMULATION IN CONJUNCTION WITH FASTING, LOW-FAT MEALS, OR HIGH-FAT MEALS1,2
Kahan, B. D., Dunn, J. L., Fitts, C. T., Buren, D. V., Wombolt, D. G., Pollak, R., Carson, R. W., Alexander, W. J., Choc, M. G., Wong, R., et al. (1995) · Transplantation · doi:10.1097/00007890-199502270-00011 · Cited by 215
Lipid Formulation Strategies for Enhancing Intestinal Transport and Absorption of P-Glycoprotein (P-gp) Substrate Drugs: In vitro/In vivo Case Studies
Constantinides, P. P., & Wasan, K. M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20780 · Cited by 208
Self-citation
ADME Evaluation in Drug Discovery. 5. Correlation of Caco-2 Permeation with Simple Molecular Properties
Hou, T., Zhang, W., Xia, K., Qiao, X. B., & Xu, X. J. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci049884m · Cited by 204
Computational prediction of formulation strategies for beyond-rule-of-5 compounds
Bergström, C. A. S., Charman, W. N., & Porter, C. J. H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.005 · Cited by 197
Formulation of amphotericin B as nanosuspension for oral administration
Kayser, O. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00686-5 · Cited by 187
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 184
Saquinavir, an HIV Protease Inhibitor, Is Transported by P-Glycoprotein
Kim, A. E., Dintaman, J. M., Waddell, D. S., & Silverman, J. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37742-0 · Cited by 177
Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties
Gu, C., Li, H., Levons, J. K., Lentz, K. A., Gandhi, R. B., Raghavan, K. S., & Smith, R. L. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9236-1 · Cited by 155
Soft Gelatin Capsules (Softgels)
Gullapalli, R. P. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22151 · Cited by 150
In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin
Hintzen, F., Perera, G., Hauptstein, S., Muller, C. R., Laffleur, F., & Bernkop‐Schnürch, A. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.047 · Cited by 147
Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line
Perloff, M. D., Moltke, L. L., Marchand, J. E., & Greenblatt, D. J. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1133 · Cited by 135
The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review
Akhtar, N., Ahad, A., Khar, R. K., Jaggi, M., Aqil, M., Iqbal, Z., Ahmad, F. J., & Talegaonkar, S. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.561784 · Cited by 133
Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines.
Zgair, A., Wong, J. C. M., Lee, J. B., Mistry, J., Sivak, O., Wasan, K. M., Hennig, I. M., Barrett, D. A., Constantinescu, C. S., Fischer, P. M., et al. (2016) · Europe PMC (PubMed Central) · Cited by 130
Self-citation
Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis
Delmas, G., Park, S., Chen, Z. W., Tan, F., Kashiwazaki, R., Zarif, L., & Perlin, D. S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2704-2707.2002 · Cited by 110
Development of Amphotericin B-Loaded Cubosomes Through the SolEmuls Technology for Enhancing the Oral Bioavailability
Yang, Z., Tan, Y., Chen, M., Dian, L., Shan, Z., Peng, X., & Wu, C. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9876-2 · Cited by 99
Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis
Mistro, S., Maciel, I. D. M., de Menezes, R. G., Maia, Z. P. G., Schooley, R. T., & Badaró, R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis290 · Cited by 92
Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation
Gershkovich, P., Wasan, E. K., Lin, M., Sivak, O., Leon, C. G., Clement, J. G., & Wasan, K. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp140 · Cited by 83
Self-citation
Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products
Kang, S. P., & Ratain, M. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0663 · Cited by 79
Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection
Xu, P., Yang, Z., Chen, M., Yang, M., Chen, J., & Fang, W. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s54967 · Cited by 79
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
Johansen, H. K., & Gøtzsche, P. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000969.pub2 · Cited by 78
Enhancing drug absorption using lipids: A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections
Sachs‐Barrable, K., Lee, S. D., Wasan, E. K., Thornton, S. J., & Wasan, K. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.042 · Cited by 76
Self-citation
Amprenavir
Adkins, J. C., & Faulds, D. M. (1998) · Drugs · doi:10.2165/00003495-199855060-00015 · Cited by 74
A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model
Wasan, E. K., Gershkovich, P., Zhao, J., Zhu, X., Werbovetz, K. A., Tidwell, R. R., Clement, J. G., Thornton, S. J., & Wasan, K. M. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000913 · Cited by 63
Self-citation
Application of Lipid-Based Formulations in Drug Discovery
Chen, X., Gudmundsson, O. S., & Hageman, M. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3006433 · Cited by 63
A Review on Novel Therapeutic Strategies for the Enhancement of Solubility for Hydrophobic Drugs through Lipid and Surfactant Based Self Micro Emulsifying Drug Delivery System: A Novel Approach
Agrawal, S., Giri, T. K., Tripathi, D. K., Ajazuddin, M., & Alexander, A. (2012) · American Journal of Drug Discovery and Development · doi:10.3923/ajdd.2012.143.183 · Cited by 63
Drug permeability across a phospholipid vesicle-based barrier
Flaten, G. E., Luthman, K., Vasskog, T., & Brandl, M. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.04.001 · Cited by 62
Flushing Oral Oncology Drugs Down the Toilet
Ratain, M. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1617 · Cited by 53
Effect of Polyoxyl 35 Castor Oil and Polysorbate 80 on the Intestinal Absorption of Digoxin in vitro
Cornaire, G., Woodley, J. F., Saivin, S., Legendre, J., Decourt, S., Cloarec, A., & Houin, G. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300252 · Cited by 53
Currently Marketed Oral Lipid-Based Dosage Forms: Drug Products and Excipients
Strickley, R. G. (2007) · CRC Press eBooks · doi:10.3109/9781420017267-4 · Cited by 52
Impact of Cremophor-EL and Polysorbate-80 on Digoxin Permeability across Rat Jejunum: Delineation of Thermodynamic and Transporter Related Events Using the Reciprocal Permeability Approach
Katneni, K., Charman, S. A., & Porter, C. J. H. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20779 · Cited by 49
Amphotericin B colloidal dispersion: an improved antifungal therapy
Guo, L. S. S. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00104-1 · Cited by 49
Effects of Lipid-Based Oral Formulations on Plasma and Tissue Amphotericin B Concentrations and Renal Toxicity in Male Rats
Risovic, V., Boyd, M. C., Choo, E., & Wasan, K. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3339-3342.2003 · Cited by 48
Self-citation
Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles
Sheu, M., Chen, Y., Su, C.-Y., Jhan, H.-J., & Ho, H.-O. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s95194 · Cited by 40
Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe
Schmitt, C., Kaeser, B., Riek, M., Bech, N., & Kreuzer, C. (2010) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp48192 · Cited by 38
In Vitro and In Vivo Evaluation of a Water-in-Oil Microemulsion System for Enhanced Peptide Intestinal Delivery
Liu, D., Kobayashi, T., Russo, S. M., Li, F., Plevy, S. E., Gambling, T. M., Carson, J. L., & Mumper, R. J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9441-7 · Cited by 35
Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases
Rao, S., Tan, A., Thomas, N., & Prestidge, C. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.013 · Cited by 34
In vitro activity of amphotericin B cochleates against Leishmania chagasi
Sesana, A. M., Monti-Rocha, R., Vinhas, S. A., Morais, C. G., Dietze, R., & Lemos, E. M. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000200022 · Cited by 33
Softgels: Consumer perceptions and market impact relative to other oral dosage forms
Jones, W. J., & Francis, J. J. (2000) · Advances in Therapy · doi:10.1007/bf02853160 · Cited by 28
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
Sivak, O., Gershkovich, P., Lin, M., Wasan, E. K., Zhao, J., Owen, D., Clement, J. G., & Wasan, K. M. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-135 · Cited by 27
Self-citation
Preliminary evaluation of a novel oral delivery system for rhPTH1-34: In vitro and in vivo
Guo, L., Erli, M., Zhao, H., Long, Y., Zheng, C., & Duan, M. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.029 · Cited by 24
Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice
Gershkovich, P., Wasan, E. K., Sivak, O., Li, R.-N., Zhu, X., Werbovetz, K. A., Tidwell, R. R., Clement, J. G., Thornton, S. J., & Wasan, K. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp465 · Cited by 23
Self-citation
Amphotericin B cochleates: a vehicle for oral delivery.
Perlin, D. S. (2004) · PubMed · Cited by 18
Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non‐toxic chemotherapy
Gupta, P. K., Jaiswal, A. K., Asthana, S., Venkatesh Teja, B., Shukla, P., Shukla, M., Sagar, N., Dube, A., Rath, S. K., & Mishra, P. R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13149 · Cited by 18
Assessing the Antifungal Activity of a New Oral Lipid-Based Amphotericin B Formulation Following Administration to Rats Infected withAspergillus Fumigatus
Risovic, V., Rosland, M., Sivak, O., Wasan, K. M., & Bartlett, K. H. (2007) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040601077349 · Cited by 17
Self-citation
Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral sandimmune to neoral
Mendez, R., Abboud, H. E., Burdick, J. F., Copley, B., Freeman, R. B., Batiuk, T. D., Cooney, G. F., & Barbeito, R. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88276-4 · Cited by 17

Research works printed but not linked: 11

Porter CJH., 2007, Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs, 185
Griffin B., 2012, Am Pharm Rev
10.1097/00007890-199559040-00011 · DOI
Gao P. MW., 2007, Oral lipid-based formulations enhancing the bioavailability of poorly water soluble drugs
Martins S, 2007, Int J Nanomed, 2, 595
2013, Abelcet®
Johansen HK, 2014, Cochrane Database Syst Rev, CD000969
Chen Y-C, 2015, Int J Nanomed, 10, 7265
Zgair A, 2016, Am J Trans Res, 8, 3448
Perlin DS., 2004, Curr Opin Investig Drugs, 5, 198
Yang Z, 2014, Int J Nanomed, 9, 327

Sorted by citations

Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 945
Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery
Azman, M., Sabri, A. H. B., Anjani, Q. K., Mustaffa, M. F., & Hamid, K. A. (2022) · Pharmaceuticals · doi:10.3390/ph15080975 · Cited by 277
Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability
Nguyen, T., Duong, V., & Maeng, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071103 · Cited by 272
Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems
Moreno‐Alcántar, G., Picchetti, P., & Casini, A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202218000 · Cited by 207
Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs
Nyamba, I., Sombié, C. B., Yabré, M., Zimé-Diawara, H., Yaméogo, J. B. G., Ouédraogo, S., Lechanteur, A., Semdé, R., & Évrard, B. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114513 · Cited by 188

See all 225

Authors: Savla, R., Browne, J., Plassat, V., Wasan, K. M., & Wasan, E. K.
Affiliations: Catalent (United States) (US)
Cerenis Therapeutics (France) (FR)
University of Saskatchewan (CA)
Corresponding author: Savla, Ronak
ORCID: Savla, Ronak
Plassat, Vincent
Wasan, Kishor M.
Wasan, Ellen K.
Venue: Drug Development and Industrial Pharmacy
Publisher: Informa UK Limited
Published: 2017-07-06
Volume: 43
Issue: 11
Pages: 1743-1758
ISSN: 0363-9045 (ISSN-L)
1520-5762
DOI: 10.1080/03639045.2017.1342654
OpenAlex: W2732877934
Cited by: 225
References: 75
Citations by year: 2026: 12 · 2025: 24 · 2024: 23 · 2023: 23 · 2022: 27 · 2021: 39 · 2020: 42 · 2019: 21 · 2018: 14
FWCI: 10.88
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Drug Development and Industrial Pharmacy (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Figshare (submittedVersion, cc-by)
Figshare (cc-by)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords: lipid-based drug delivery, bioavailability enhancement, FDA-approved drugs, physicochemical properties, molecular properties
MeSH terms: Biological Availability, Chemistry, Pharmaceutical, Humans, Lipids, United States, Drug Delivery Systems, Drug Approval

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Review and analysis of FDA approved drugs using lipid-based formulations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks